Evotec and Bristol Myers Squibb Advance Novel Molecular Glue Degrader BMS-986506 into Phase 1 Trial for Kidney Cancer
核心洞察
Bristol Myers Squibb (搜索) has initiated a Phase 1 clinical study of BMS-986506 (搜索), a cereblon E3 ligase (搜索) modulator, for treating advanced clear cell renal cell carcinoma (搜索), the most common form of kidney cancer (搜索).
The molecular glue degrader was developed through Evotec's strategic protein degradation collaboration with BMS, combining high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities.
This first-in-human study marks a significant milestone in the partnership, triggering a $10 million milestone payment to Evotec and representing the transition of their oncology platform into clinical development.
Bristol Myers Squibb (搜索) has initiated dosing of the first patient in a Phase 1 clinical study evaluating BMS-986506 (搜索), a novel cereblon E3 ligase (搜索) modulator, for the treatment of advanced clear cell renal cell carcinoma (搜索). The milestone represents a transformative moment in the strategic protein degradation collaboration between Bristol Myers Squibb and Evotec, triggering a $10 million milestone payment to the German drug discovery company.
The first-in-human study brings into the clinic a novel CELMoD (搜索) or "molecular glue" candidate jointly generated through Evotec's fully integrated drug discovery platform. This platform combines high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities, selectively prompting cancer cells to eliminate disease-driving proteins.
Strategic Collaboration Delivers Clinical Milestone
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the significance of this advancement: "In this unique collaboration, we follow a systematic approach to discovering molecular glues with tremendous therapeutic potential. Together with Bristol Myers Squibb (搜索), and building on Evotec's PanOmics and PanHunter platforms, we have identified a broad portfolio of high-potential molecular glue drug candidates that are now beginning to enter clinical development."
The collaboration, initiated in 2018 and expanded in 2022, combines Evotec's proprietary platforms with Bristol Myers Squibb (搜索)'s industry-leading library of CELMoDs agents. The partnership aims to discover and develop a leading pipeline of molecular glue degraders (搜索) for high-value targets in oncology and beyond.
Addressing the Undruggable Proteome
Molecular glue degraders (搜索) represent a significant advancement over conventional small molecule therapeutics. While traditional drugs work through drug-induced interference with protein activity, limiting them to agonistic or antagonistic functions and rendering about 90% of proteins "undruggable," molecular glue degraders operate through a fundamentally different mechanism.
These compounds induce interactions between an E3 ubiquitin ligase (搜索) and a molecular target, resulting in ubiquitination and degradation of the recruited protein. This event-driven mechanism significantly expands the range of the druggable proteome. Importantly, the molecular glue is not degraded in the process and can trigger the degradation process many times over, leading to longer-lasting therapeutic effects compared to conventional therapies that require daily dosing regimens.
Advanced Platform Technology
The development of BMS-986506 (搜索) leverages Evotec's comprehensive technology stack, including PanOmics, the company's high-performance multi-omics screening platform, and PanHunter, its AI-supported data omics analytics platform. Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles.
The PanHunter platform supports the integration and analysis of these data sets, enabling the selection of the most promising CELMoDs for further progression into lead optimization. This systematic approach has generated what Dohrmann describes as "a broad portfolio of high-potential molecular glue drug candidates" now entering clinical development.
Targeting Kidney Cancer
Clear cell renal cell carcinoma (搜索) represents the most common form of kidney cancer (搜索), and the initiation of this Phase 1 study aims to establish a new treatment paradigm for patients with advanced disease. The study highlights the transition of the Evotec-BMS oncology platform into clinical evaluation and reflects a robust pipeline of molecular glues being advanced as treatment options for different cancer types.
According to Dohrmann, "Molecular glues have the potential to address significant unmet medical need not only in oncology, but far beyond, by targeting previously undruggable, disease-causing proteins and thereby aiming to reshape future standards of care."
The clinical progression of BMS-986506 (搜索) validates Evotec's high-performance multi-omics screening and AI-supported data analytics and drug design capabilities, marking the first clinical milestone in the strategic protein degradation partnership with Bristol Myers Squibb (搜索).